INDV offering history
Every offering-related filing in Indivior Pharmaceuticals, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 536 filings back to Dec 2, 2014.
| Date | Filing | What it means | |
|---|---|---|---|
| Mar 17, 2026 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Jan 26, 2026 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Dec 23, 2014 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
INDV offering FAQ
When did INDV last execute an offering?
Per SEC filings, Indivior Pharmaceuticals, Inc.'s most recent priced offering document is a 8-K filed 2026-03-17. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did INDV last announce or register an offering?
No offering registration (S-1/S-3/F-1/F-3) appears in the filings reviewed back to 2014-12-02.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.